Anti-tumor composition

Details Anti-tumor composition Anti-tumor composition

2006-01-31

2006-01-31

Low, Christopher S. F. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S519000, C514S647000, C514S592000, C514S646000, C514S598000, C424S649000

Reexamination Certificate

active

06992106

ABSTRACT:
The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

REFERENCES:
patent: 4140707 (1979-02-01), Cleare et al.
patent: 4935450 (1990-06-01), Cone, Jr.
patent: 5525632 (1996-06-01), Obsumi et al.
patent: 5674906 (1997-10-01), Hatanaka et al.
patent: 5700826 (1997-12-01), Mjalli et al.
patent: 5728687 (1998-03-01), Bissery
patent: 5731353 (1998-03-01), Obsumi et al.
patent: 5844001 (1998-12-01), McClay et al.
patent: 6462087 (2002-10-01), Morinaga et al.
patent: 0 276 051 (1988-07-01), None
patent: 0 641 767 (1995-03-01), None
patent: WO 02/074229 (2002-09-01), None
patent: WO 91/04058 (1991-04-01), None
patent: WO 92/16486 (1992-10-01), None
patent: WO 95/00129 (1995-01-01), None
patent: WO 95/20960 (1995-08-01), None
patent: WO 97/08184 (1997-03-01), None
patent: WO 98/33481 (1998-08-01), None
patent: WO 00/09097 (2000-02-01), None
patent: WO 00/48590 (2000-08-01), None
patent: WO 01/12579 (2001-02-01), None
patent: WO 02/056692 (2002-07-01), None
The Merck Index, 11th edition; published by Merck & Co., Inc. 1989, Rathway, NJ, USA; p. 276, entry ·1828.
Lippincott's Illustrated Reviews: Pharmacology; 1997 Lippincott-Raven Publishers; p. 395-396.
“Enhancing and Inhibitory Effects of Some Stilbene and Steroid Compounds on Induction of Hepatoma in Rats Fed 3'-Methyl-4-(Dimethylamino)Azobenzene” Gann, 69, No. 3, pp. 375-382, Jun. 1978 (Chiba).
Anti-Leukaemic Compounds Derived from Stilbenes in Picea Abies Bark:, Phytochemisty, vol. 33, No. 4, 1993 pp. 813-816.
Tashiro, Nippon Kagaku Kalshi (1988), 684-90 Abstract Only.
American Assosiation for Cancer Research, Eighty-Ninth Annual Meeting, Proceedings, Mar. 28-Apr. 1, 1998, New Orleans, LA., vol. 39—Mar. 1998.
B. Nakata,et al., Cancer Chemotherapy and Pharmacology, vol. 35, No. 6, pp. 511-518, XP-008010359, “Synergistic Interaction Between Cisplatin and Tamoxifen Delays the Emergence of Cisplatin Resistance in Head and Neck Cancer Cell Lines”, 1995.
E. F. McClay, et al., British Journal of Cancer, vol. 70, No. 3, pp. 449-452, XP-008010360, “Tamoxifen Delays the Development of Resistance to Cisplatin in Human Melanoma and Ovarian Cancer Cell Lines”, 1994.
Patent Abstracts of Japan, JP 56-103192, Aug. 18, 1981.
M. Cushman, et al., Journal of Medicinal Chemistry, vol. 34, No. 8, pp. 2579-2588, XP-000571676, “Synthesis and Evaluation of Stilbene and Dihydrostilbene Derivatives as Potential Anticancer Agents That Inhibit Tubulin Polymeraztion”, 1991.
J. A. Woods, et al., British Journal of Cancer, vol. 71, No. 4, pp. 705-711, XP-000978556, “The Interaction with Tubulin of a Series of Stilbenes Based on Combretastatin A-4”, 1995.

Affiliated with

Also associated with

Rating

Anti-tumor composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-tumor composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3540539